News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioenvision (BIOV) Release: Clofarabine Achieves High Response Rates In Acute Myeloid Leukaemia -AML-; Three Fold Increase In Response Rates Compared With Current Standard Of Care


10/19/2005 5:12:22 PM

Bioenvision, Inc. (Nasdaq: BIVN) announced today that results presented at the 46th American Society of Haematology Meeting (ASH) showed that clofarabine achieved a three fold greater overall response rate than current best standard of care in older patients with Acute Myeloid Leukaemia (AML) who were unsuitable for intensive chemotherapy.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES